140 related articles for article (PubMed ID: 37906272)
21. Intraductal carcinoma of the prostate (IDC-P) lowers apparent diffusion coefficient (ADC) values among intermediate risk prostate cancers.
Currin S; Flood TA; Krishna S; Ansari A; McInnes MDF; Schieda N
J Magn Reson Imaging; 2019 Jul; 50(1):279-287. PubMed ID: 30585372
[TBL] [Abstract][Full Text] [Related]
22. Prebiopsy multiparametric MRI and PI-RADS version 2.0 for differentiating histologically benign prostate disease from prostate cancer in biopsies: A retrospective single-center comparison.
Tosun M; Uslu H
Clin Imaging; 2021 Oct; 78():98-103. PubMed ID: 33773450
[TBL] [Abstract][Full Text] [Related]
23. [Analysis of the relationship between PI-RADS scores and the pathological results of targeted biopsy based on MRI].
Wang YM; Shang JW; Dong L; Liang LH; Zhao RZ; Liang C; Wang SQ; Xia W; Cheng G; Hua LX
Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):942-947. PubMed ID: 37968079
[No Abstract] [Full Text] [Related]
24. Magnetic Resonance Imaging-based T-staging to Predict Biochemical Recurrence after Radical Prostatectomy: A Step Towards the iTNM Classification.
Baboudjian M; Gondran-Tellier B; Touzani A; Martini A; Diamand R; Roche JB; Lacetera V; Beauval JB; Roumeguère T; Simone G; Benamran D; Fourcade A; Fiard G; van den Bergh RCN; Peltier A; Ploussard G
Eur Urol Oncol; 2023 Aug; 6(4):406-413. PubMed ID: 36280445
[TBL] [Abstract][Full Text] [Related]
25. Comparison of 3 T mpMRI and pelvic CT examinations for detection of lymph node metastases in patients with prostate cancer.
Valentin B; Arsov C; Ullrich T; Demetrescu D; Morawitz J; Al-Monajjed R; Quentin M; Kirchner J; Esposito I; Albers P; Antoch G; Schimmöller L
Eur J Radiol; 2022 Feb; 147():110110. PubMed ID: 34952329
[TBL] [Abstract][Full Text] [Related]
26. Predictive clinical features for negative histopathology of MRI/Ultrasound-fusion-guided prostate biopsy in patients with high likelihood of cancer at prostate MRI: Analysis from a urologic outpatient clinic1.
Apfelbeck M; Pfitzinger P; Bischoff R; Rath L; Buchner A; Mumm JN; Schlenker B; Stief CG; Chaloupka M; Clevert DA
Clin Hemorheol Microcirc; 2020; 76(4):503-511. PubMed ID: 33337358
[TBL] [Abstract][Full Text] [Related]
27. Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy.
Thaiss WM; Moser S; Hepp T; Kruck S; Rausch S; Scharpf M; Nikolaou K; Stenzl A; Bedke J; Kaufmann S
World J Urol; 2022 Oct; 40(10):2431-2438. PubMed ID: 35922717
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance and risk factors of International Society of Urological Pathology (ISUP) grade upgrading in prostate cancer patients undergoing robot-assisted radical prostatectomy.
Takeshima Y; Yamada Y; Teshima T; Fujimura T; Kakutani S; Hakozaki Y; Kimura N; Akiyama Y; Sato Y; Kawai T; Yamada D; Kume H
BMC Cancer; 2021 May; 21(1):501. PubMed ID: 33947348
[TBL] [Abstract][Full Text] [Related]
29. Detection of ISUP ≥2 prostate cancers using multiparametric MRI: prospective multicentre assessment of the non-inferiority of an artificial intelligence system as compared to the PI-RADS V.2.1 score (CHANGE study).
Rouvière O; Souchon R; Lartizien C; Mansuy A; Magaud L; Colom M; Dubreuil-Chambardel M; Debeer S; Jaouen T; Duran A; Rippert P; Riche B; Monini C; Vlaeminck-Guillem V; Haesebaert J; Rabilloud M; Crouzet S
BMJ Open; 2022 Feb; 12(2):e051274. PubMed ID: 35140147
[TBL] [Abstract][Full Text] [Related]
30. Zone-specific computer-aided diagnosis system aimed at characterizing ISUP ≥ 2 prostate cancers on multiparametric magnetic resonance images: evaluation in a cohort of patients on active surveillance.
Arber T; Jaouen T; Campoy S; Rabilloud M; Souchon R; Abbas F; Moldovan PC; Colombel M; Crouzet S; Ruffion A; Neuville P; Rouvière O
World J Urol; 2023 Dec; 41(12):3527-3533. PubMed ID: 37845554
[TBL] [Abstract][Full Text] [Related]
31. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
[TBL] [Abstract][Full Text] [Related]
32. Risk and predictors of adverse pathology after radical prostatectomy in patients diagnosed with IUSP 1-2 prostate cancer at MRI-targeted biopsy: a multicenter analysis.
Kesch C; Pantea V; Soeterik T; Marquis A; la Bombarda G; Morlacco A; Barletta F; Radtke JP; Darr C; Preisser F; Zattoni F; Marra G; van den Bergh RCN; Hadaschik B; Gandaglia G;
World J Urol; 2023 Feb; 41(2):427-434. PubMed ID: 36534151
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of Prostate Cancer in PI-RADS Version 2.1 Transition Zone Atypical Nodules Upgraded by Abnormal DWI: Correlation With MRI-Directed TRUS-Guided Targeted Biopsy.
Lim CS; Abreu-Gomez J; Carrion I; Schieda N
AJR Am J Roentgenol; 2021 Mar; 216(3):683-690. PubMed ID: 32755208
[No Abstract] [Full Text] [Related]
34. Prostate MRI percentage tumor involvement or "PI-RADS percent" as a predictor of adverse surgical pathology.
Ratnani P; Dovey Z; Parekh S; Sobotka S; Shukla D; Davis A; Roshandel R; Wagaskar V; Jambor I; Lundon DJ; Wiklund P; Kyprianou N; Menon M; Tewari A
Prostate; 2022 Jun; 82(9):970-983. PubMed ID: 35437769
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathological factors associated with pathological upgrading from biopsy to prostatectomy in patients with ISUP grade group ≤2 prostate cancer.
Li X; Wang ZX; Zhu YP; Wang J; Yin YS; Zeng XY
Asian J Androl; 2022; 24(5):487-493. PubMed ID: 35170453
[TBL] [Abstract][Full Text] [Related]
36. Multiparametric MRI with in-bore targeted biopsy in the diagnostic pathway of prostate cancer: Data from a single institution experience.
Nawfal G; Sarkis J; Assaf S; Mjaess G; Abi Chebel J; Semaan A; Alkassis M; Nemr E; Kamel G; Ayoub N; Sarkis P
Urol Oncol; 2021 Nov; 39(11):781.e9-781.e15. PubMed ID: 33676850
[TBL] [Abstract][Full Text] [Related]
37. Predicting early outcomes in patients with intermediate- and high-risk prostate cancer using prostate-specific membrane antigen positron emission tomography and magnetic resonance imaging.
Meijer D; van Leeuwen PJ; Donswijk ML; Boellaard TN; Schoots IG; van der Poel HG; Hendrikse HN; Oprea-Lager DE; Vis AN
BJU Int; 2022 Jan; 129(1):54-62. PubMed ID: 34028165
[TBL] [Abstract][Full Text] [Related]
38. Nonsuspicious prebiopsy multiparametric MRI: is prostate biopsy still necessary?
Anastay V; Gondran-Tellier B; McManus R; Delonca R; Akiki A; Gaillet S; Delaporte V; Andre M; Daniel L; Karsenty G; Lechevallier E; Boissier R; Baboudjian M
Abdom Radiol (NY); 2020 Dec; 45(12):4160-4165. PubMed ID: 32902661
[TBL] [Abstract][Full Text] [Related]
39. MRI combined with PSA density in detecting clinically significant prostate cancer in patients with PSA serum levels of 4∼10ng/mL: Biparametric versus multiparametric MRI.
Han C; Liu S; Qin XB; Ma S; Zhu LN; Wang XY
Diagn Interv Imaging; 2020 Apr; 101(4):235-244. PubMed ID: 32063483
[TBL] [Abstract][Full Text] [Related]
40. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
